OKYO Pharma Ltd (OKYO)

[PennystockID2017]

Today's news is very big should see $3.50 today. OKYO is up 11% in london trading

[LuckyLovie]

By the looks of the trading chart hit high of 6+...I betcha there are no shortages of dry eyes anywhere...allot are wet crying eyes,honey I bought at the high again,YUP maybe next yr will break even...typical buy on the rumor, sell the news...lol

[Boris the Spider]

$5B dry eye market. OKYO well positioned now.

This will be a $10 stock near term. Once approved, blue sky territory because it is a lipid vehicle for dry eye plus antiinflammatory for irritation and pain relief. I love this stock.

[Spicknspan]

DAMN!

[behzadzorro]

Is it real?!

[INFINITI]

Bam

[INFINITI]

Let’s gooo

[makinezmoney]

$OKYO: BOOoommmmmmmmmmmmmmmm...............just hit 6.50


Finally got Discovered ??


Looks like it


GOOOOOOOOOOOOO $OKYO

[makinezmoney]

$OKYO: Got the FDA IND Clearance for Dry-EYE-Disease


Just 2 weeks ago.

This bad boy has alotta upside .......... remember $KALA ???


Now at $1.99

https://twitter.com/okyopharma









GO $OKYO

[crudeoil24]

OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The GPCRs is the family of membrane proteins involved in many biological processes. GPCRs is used for the treatment of various conditions, including cardiovascular disease, cancer, and diabetes. Its product pipeline includes OK-101 for Dry Eye Disease (DED), OK-101 for Non-ophthalmic Indications, and OK-201 to treat corneal neuropathic pain. The OK-101 is its lead preclinical product candidate, which is focused on keratoconjunctivitis sicca commonly known as DED which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The OK-201 is a non-opioid analgesic for ocular pain management without side effects and the potential abuse associated with opioid medications.